MarketInOut Stock Screener Log In | Sign Up

Aclaris Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/06/2026 16:00
Aclaris Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization599.02 mln
Float117 mln
Earnings Date02/25/2027

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

55.61
Highly suspicious

1-Year Forecast

10.36
Transformational upside

Relative Strength

86 / 100
Strongly outperforming

Debt / Equity

0.02
Debt-free

Pre-Tax Margin

-922%
Severely loss-making

Business Description

Aclaris Therapeutics is a US-based clinical-stage biopharmaceutical company focused on developing new treatments for immune and inflammatory diseases. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is advancing several drug candidates targeting conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, and other respiratory and autoimmune disorders. Its pipeline spans multiple stages of clinical testing, with therapies designed to work through a range of biological mechanisms that regulate immune cell activity.

Key Fundamentals

EPS-0.59
ROE-60.77
RPS0.06
ROIC-94.50
ROA-41.91
EBITDA, mln-75.22
EV / EBITDA-6.88
EV / EBIT-6.84
Revenue, mln8.22
EV / Revenue62.99

Quote Details

Last 3.90
Change 0.29 (8.03%)
Open 3.62
Volume 3,526,327
Turnover 13,752,676
Average Volume 2,891,016

Financial Ratios

Pre-Tax Profit Margin-922
Leverage Ratio1.30
Current Ratio3.46
Price / Book4.29
Price / Tangible Book4.29
Debt / Equity0.02
Price / Sales59.69

Financial Strength

Altman Z-Score-2.65
Piotroski F-Score 4 / 9
Beneish M-Score55.61
1-Year Target Price10.36
Short Ratio3.86
Short % of Float11.59

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -1.76% 45 / 100   
1 Month 2.9% 80 / 100   
2 Months -29.48% 19 / 100   
6 Months -20.89% 28 / 100   
1 Year 72.57% 96 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog